NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead managerin the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. The underwritten public offering is valued at
The capital raised will be used for various activities, including advancing clinical trials, research, manufacturing practices and working capital.
Chardan has participated in advisory and capital raising transactions totaling more than $2 billion in 2018.
Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
Learn more about Chardan: www.chardan.com
Media Contact: Emily Levine, Chardanelevine@chardan.com (646) 465-9018
Tom Rozycki, Prosek Partnerstrozycki@prosek.com(646) 503-5657
View original content:http://www.prnewswire.com/news-releases/chardan-serves-as-lead-manager-for-krystal-biotech-300735480.html
SOURCE Chardan Capital Markets, LLC
Subscribe to our Free Newsletters!